Kisspeptin: cells, hormones, eggs
The hormone results are striking. The mouse-neuron work offers an unusually close look at the signal that precedes them.
KISS1R and the hormone response
Kisspeptin is a family of peptides made from the KISS1 gene product. Its receptor, KISS1R or GPR54, activates GnRH neurons; GnRH then stimulates the pituitary to release LH and FSH, which support downstream sex-steroid production. The cellular work on GnRH neurons and the human and mouse genetics of GPR54 approach that biology from different directions.
In the genetic study, loss-of-function GPR54 mutations were associated with failure of puberty and low reproductive hormones in humans. Mice lacking Gpr54 reproduced the phenotype. Those genetic consequences make a compelling case, to me, for taking the pathway seriously. Giving extra peptide to an adult asks a separate experimental question.
Mouse neurons under observation
The 2008 electrophysiology experiment worked with mouse GnRH neurons in vitro, using brain slices. Kisspeptin depolarized the neurons through a PLC–IP3–calcium pathway. Depolarization is the electrical shift that helps a neuron fire. Closing potassium channels and opening non-selective cation channels were involved in that response.
At 100 nM, the reported electrical shift was 6 ± 1 mV, with firing increased by 87 ± 4% in about 75% of adult GnRH neurons. These are measurements of cells under experimental conditions. The result describes a mechanism at unusually close range; it gives no direct measurement of a person's desire.
That intimacy of scale appeals to me. Before the hormone values and fertility outcomes, there is an observable change in an individual cell.
Hormone findings in men
The 2011 human experiment used intravenous kisspeptin-10 in healthy men. A bolus raised LH from 4.1 to 12.4 IU/L at 30 minutes. In a separate continuous-infusion part of the study, mean LH rose from 5.2 to 14.1 IU/L and LH pulse frequency from 0.7 to 1.0 pulses/hour. At a higher infusion rate, serum testosterone rose from 16.6 to 24.0 nmol/L.
Those findings establish an acute hormone response under supervision. I would be asking more of the experiment than it measured if I translated that testosterone rise into a prediction about sexual satisfaction or lasting symptom relief.
Amenorrhea; IVF triggering
In five women with hypothalamic amenorrhea, intravenous kisspeptin-54 increased LH pulses from 1.6 to 5.0 per 8 hours compared with vehicle. At the highest continuous infusion rate the response faded during the infusion, a phenomenon called tachyphylaxis. The successful stimulation and the fading response occurred within the same research programme. Both matter to any account of sustained hormone activity.
The IVF trial had a different task. In a Phase 2 randomized study of 60 women at high risk of ovarian hyperstimulation syndrome, kisspeptin-54 triggered oocyte maturation in 95% of women. There were no cases of moderate, severe or critical OHSS in that trial. Oocytes are egg cells; maturation was the immediate job of the experimental trigger within a much larger IVF process.
A job as specific as egg maturation earns my respect. The observed absence of those OHSS cases is encouraging, while the study's size and selected population remain attached to the finding.
Intranasal kisspeptin-54
The 2025 delivery experiment measured LH release after intranasal kisspeptin-54 in healthy men, healthy women and women with hypothalamic amenorrhea. The reported LH increases were +4.4 IU/L, +1.4 IU/L and +4.4 IU/L respectively. No adverse events were reported in the study, and the formulation was stable for up to 60 days at 4°C.
The route changes what can be attempted in research. It does not establish a home treatment or resolve the questions around repeated exposure. The hormone response is the finding to credit here.
Kisspeptin safety
Community accounts describe increased sexual interest, emotional closeness, spontaneous erections and sometimes renewed cycle activity; others describe no perceptible change. Warmth, headache, nausea and local irritation also appear. These are anecdotal accounts, not clinical evidence, and they cannot establish how often an effect occurs or whether kisspeptin caused it.
Kisspeptin remains investigational, with no approved indication. The clinical-status review published in 2025 identified 29 interventional trials in searches through February 2023. The selected supervised studies here leave long-term safety, pregnancy and hormone-sensitive conditions unresolved. Their results also cannot establish the identity, purity or sterility of material outside those study settings.
Further work could give that enthusiasm firmer ground: I want repeated-exposure safety findings and replication across research centres before the clinical possibilities become easier to assess. For desire and distress specifically, the bremelanotide trials ask different questions.